Cargando…

The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis

BACKGROUND: Immunotherapy has become an essential part of cancer treatment after showing great efficacy in various malignancies. However, its effectiveness in pancreatic ductal adenocarcinoma (PDAC), especially in resectable pancreatic cancer, has not been studied. The primary objective of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amin, Saber, Baine, Michael, Meza, Jane, Lin, Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285784/ https://www.ncbi.nlm.nih.gov/pubmed/32517661 http://dx.doi.org/10.1186/s12885-020-07016-8

Ejemplares similares

The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database
por: Amin, Saber, et al.
Publicado: (2020)

The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database
por: Amin, Saber, et al.
Publicado: (2020)

The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor
por: Amin, Saber, et al.
Publicado: (2020)

Association of Immunotherapy With Survival Among Patients With Brain Metastases Whose Cancer Was Managed With Definitive Surgery of the Primary Tumor
por: Amin, Saber, et al.
Publicado: (2020)

The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
por: Amin, Saber, et al.
Publicado: (2021)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Marital Status and Survival in Pancreatic Cancer Patients: A SEER Based Analysis
por: Baine, Michael, et al.
Publicado: (2011)

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?
por: Ryckman, Jeffrey M., et al.
Publicado: (2021)

The impact of neoadjuvant immunotherapy on perioperative outcomes and survival after esophagectomy for esophageal cancer
por: Wong, Lye-Yeng, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
por: Shukla, Nikhil, et al.
Publicado: (2021)

Dancing with the Surgeon: Neoadjuvant and Adjuvant Immunotherapies from the Medical Oncologist’s Perspective
por: Park, Sehhoon
Publicado: (2023)

Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival
por: Morganti, Alessio G., et al.
Publicado: (2019)

Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results
por: Chick, Robert Connor, et al.
Publicado: (2023)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Neoadjuvant and Adjuvant Therapy in Operable Pancreatic Cancer: Both Honey and Milk (but No Bread?)
por: Søreide, Kjetil
Publicado: (2021)

Impact of neoadjuvant and adjuvant radiotherapy on disease-specific survival in patients with stages II–IV rectal cancer
por: Wu, Yinying, et al.
Publicado: (2017)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
por: Wezel, Felix, et al.
Publicado: (2017)

Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
por: Yu, Irene, et al.
Publicado: (2023)

The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
por: Kleeff, Jörg, et al.
Publicado: (2016)

Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study
por: Pu, Ning, et al.
Publicado: (2023)

Impact of glucocorticoids on the efficacy of neoadjuvant chemoradiotherapy and survival of patients with locally advanced rectal cancer: a retrospective study
por: Huang, Xiaoxue, et al.
Publicado: (2023)

Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy
por: Matsui, Hiroto, et al.
Publicado: (2017)

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
por: Szeto, Chun Ho, et al.
Publicado: (2021)

Neoadjuvant and adjuvant therapy in esophageal cancer
por: Weiss, Jennifer A., et al.
Publicado: (2023)

Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis
por: Klein, Jonathan, et al.
Publicado: (2019)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases
por: Xia, Lin-Yu, et al.
Publicado: (2020)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis
por: Kuo, Yu-Hsuan, et al.
Publicado: (2022)

Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis
por: Krajewski, Wojciech, et al.
Publicado: (2021)

Conversion Surgery for Pancreatic Cancer—The Impact of Neoadjuvant Treatment
por: Klaiber, Ulla, et al.
Publicado: (2020)

The association of health insurance with the survival of cancer patients with brain metastases at diagnosis
por: Kolomaya, Alex, et al.
Publicado: (2021)

Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
por: Lin, Jian-Xian, et al.
Publicado: (2022)

Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis
por: Domínguez-Muñoz, Juan Enrique, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_68sujtpm1tckh1lfupka0n26nb